Business Description
Beximco Pharmaceuticals PLC
ISIN : US0885792061
Share Class Description:
STU:R2WA: DRCompare
Compare
Traded in other countries / regions
BXPHARMA.BangladeshBXP.UKR2WA.Germany IPO Date
2013-11-13Description
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.64 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | 0.24 | |||||
Interest Coverage | 16.87 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 5.15 | |||||
WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.3 | |||||
3-Year EBITDA Growth Rate | 8.9 | |||||
3-Year EPS without NRI Growth Rate | 10.3 | |||||
3-Year FCF Growth Rate | 22.6 | |||||
3-Year Book Growth Rate | 9.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 16.04 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 10.82 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 52.24 | |||||
9-Day RSI | 52.83 | |||||
14-Day RSI | 52.86 | |||||
3-1 Month Momentum % | -19.15 | |||||
6-1 Month Momentum % | -26.21 | |||||
12-1 Month Momentum % | -9.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.13 | |||||
Quick Ratio | 1.89 | |||||
Cash Ratio | 0.76 | |||||
Days Inventory | 198.08 | |||||
Days Sales Outstanding | 24.54 | |||||
Days Payable | 30.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 4.6 | |||||
Forward Dividend Yield % | 6.64 | |||||
Shareholder Yield % | 1.98 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 47.86 | |||||
Operating Margin % | 21.31 | |||||
Net Margin % | 16.04 | |||||
EBITDA Margin % | 24.46 | |||||
FCF Margin % | 2.57 | |||||
OCF Margin % | 9.23 | |||||
ROE % | 15.28 | |||||
ROA % | 11.27 | |||||
ROIC % | 12.9 | |||||
3-Year ROIIC % | 51.37 | |||||
ROC (Joel Greenblatt) % | 19.52 | |||||
ROCE % | 17.47 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 8.96 | |||||
Forward PE Ratio | 3.13 | |||||
PE Ratio without NRI | 8.99 | |||||
Shiller PE Ratio | 12.66 | |||||
Price-to-Owner-Earnings | 10.32 | |||||
PEG Ratio | 0.62 | |||||
PS Ratio | 1.44 | |||||
PB Ratio | 1.29 | |||||
Price-to-Tangible-Book | 1.42 | |||||
Price-to-Free-Cash-Flow | 55.88 | |||||
Price-to-Operating-Cash-Flow | 15.57 | |||||
EV-to-EBIT | 7 | |||||
EV-to-Forward-EBIT | 6.47 | |||||
EV-to-EBITDA | 6.38 | |||||
EV-to-Forward-EBITDA | 4.49 | |||||
EV-to-Revenue | 1.56 | |||||
EV-to-Forward-Revenue | 1.1 | |||||
EV-to-FCF | 53.94 | |||||
Price-to-GF-Value | 0.89 | |||||
Price-to-Projected-FCF | 1.13 | |||||
Price-to-Median-PS-Value | 0.8 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.78 | |||||
Price-to-Graham-Number | 0.75 | |||||
| Price-to-Net-Current-Asset-Value | 8.5 | |||||
Earnings Yield (Greenblatt) % | 14.27 | |||||
FCF Yield % | 1.78 | |||||
Forward Rate of Return (Yacktman) % | 13.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Beximco Pharmaceuticals PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 379.837 | ||
| EPS (TTM) (€) | 0.136 | ||
| Beta | -0.769 | ||
| 3-Year Sharpe Ratio | 0.23 | ||
| 3-Year Sortino Ratio | 0.37 | ||
| Volatility % | 49.07 | ||
| 14-Day RSI | 52.86 | ||
| 14-Day ATR (€) | 0.053391 | ||
| 20-Day SMA (€) | 0.4765 | ||
| 12-1 Month Momentum % | -9.95 | ||
| 52-Week Range (€) | 0.38 - 0.79 | ||
| Shares Outstanding (Mil) | 446.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Beximco Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Beximco Pharmaceuticals PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| First quarter earnings results for 2027 | 2026-11-30 | In 129 days | ||
| General meeting for 2026 | 2026-10-07 | In 75 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-28 | In 35 days | ||
| USD 0.038522 Cash Dividend | 2026-07-30 | In 6 days | ||
| Annual report for 2025 | 2026-07-30 | In 6 days | ||
| First quarter earnings results for 2026 | 2026-06-24 | 0.38 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-06-24 | 0.38 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-06-24 | 0.38 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2026-06-24 | 0.38 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-01-27 | 0.43 (+0.00%) |
Show
Entries
Beximco Pharmaceuticals PLC Frequently Asked Questions
What is Beximco Pharmaceuticals PLC(STU:R2WA)'s stock price today?
The current price of STU:R2WA is €0.51. The 52 week high of STU:R2WA is €0.79 and 52 week low is €0.38.
When is next earnings date of Beximco Pharmaceuticals PLC(STU:R2WA)?
The next earnings date of Beximco Pharmaceuticals PLC(STU:R2WA) is 2026-08-28 Est..
Does Beximco Pharmaceuticals PLC(STU:R2WA) pay dividends? If so, how much?
Beximco Pharmaceuticals PLC(STU:R2WA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Beximco Pharmaceuticals PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers